52North
52North
We build innovative in-vitro diagnostic and digital solutions with patients and clinicians to transform emergency care globally. Our focus is on rapid, portable diagnostics and digital triage that help clinicians identify and manage acute risks—particularly for immunosuppressed and cancer patients—so timely care can be delivered where it matters most.
Products & technology
Our Aster™ platform enables multiplex measurement across cell-based and soluble biomarkers from a single sample in a rapid, portable format. Neutrocheck® is a finger-prick blood test and companion app designed to help identify patients at risk of neutropenic sepsis. ACORN™ is a digital tool for remote triaging and management of emergency cancer care needs.
Background & mission
Founded in 2018 as a University of Cambridge spin-out, 52North combines clinical and technical expertise to reduce delays and improve decision-making in emergency care. The company has received funding from UK and US hospital venture funds, support from major cancer charities, and regulatory/innovation recognition (including UK breakthrough status for Neutrocheck®).
Location & contact
Based in Cambridge, UK. General enquiries: [email protected]. LinkedIn: https://www.linkedin.com/company/52north/